Literature DB >> 16081500

An alternative Ca2+-dependent mechanism of neuroprotection by the metalloporphyrin class of superoxide dismutase mimetics.

Joseph S Tauskela1, Eric Brunette, Natasha O'Reilly, Geoff Mealing, Tanya Comas, Tania F Gendron, Robert Monette, Paul Morley.   

Abstract

This study challenges the conventional view that metalloporphyrins protect cultured cortical neurons in models of cerebral ischemia by acting as intracellular catalytic antioxidants [superoxide dismutase (SOD) mimetics]. High SOD-active Mn(III)porphyrins meso-substituted with N,N'-dimethylimidazolium or N-alkylpyridinium groups did not protect neurons against oxygen-glucose deprivation (OGD), although lower SOD-active and -inactive para isomers protected against N-methyl-D-aspartate (NMDA) exposure. Mn(III)meso-tetrakis(4-benzoic acid)porphyrin (Mn(III)TBAP), as well as SOD-inactive metalloTBAPs and other phenyl ring- or beta-substituted metalloporphyrins that contained redox-insensitive metals, protected cultures against OGD and NMDA neurotoxicity. Crucially, neuroprotective metalloporphyrins suppressed OGD- or NMDA-induced rises in intracellular Ca2+ concentration in the same general rank order as observed for neuroprotection. Results from paraquat toxicity, intracellular fluorescence quenching, electrophysiology, mitochondrial Ca2+, and spontaneous synaptic activity experiments suggest a model in which metalloporphyrins, acting at the plasma membrane, protect neurons against OGD by suppressing postsynaptic NMDA receptor-mediated Ca2+ rises, thereby indirectly preventing accumulation of neurotoxic mitochondrial Ca2+ levels. Though neuroprotective in a manner not originally intended, SOD-inactive metalloporphyrins may represent promising therapeutic agents in diseases such as cerebral ischemia, in which Ca2+ toxicity is implicated. Conventional syntheses aimed at improving the catalytic antioxidant capability and/or intracellular access of metalloporphyrins may not yield improved efficacy in some disease models.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16081500     DOI: 10.1096/fj.05-3795fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  16 in total

Review 1.  Catalytic antioxidants to treat amyotropic lateral sclerosis.

Authors:  John P Crow
Journal:  Expert Opin Investig Drugs       Date:  2006-11       Impact factor: 6.206

Review 2.  Design of Mn porphyrins for treating oxidative stress injuries and their redox-based regulation of cellular transcriptional activities.

Authors:  Ines Batinic-Haberle; Ivan Spasojevic; Hubert M Tse; Artak Tovmasyan; Zrinka Rajic; Daret K St Clair; Zeljko Vujaskovic; Mark W Dewhirst; Jon D Piganelli
Journal:  Amino Acids       Date:  2010-05-16       Impact factor: 3.520

Review 3.  Mitochondrial metals as a potential therapeutic target in neurodegeneration.

Authors:  A Grubman; A R White; J R Liddell
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

Review 4.  Nitric oxide and peroxynitrite in health and disease.

Authors:  Pál Pacher; Joseph S Beckman; Lucas Liaudet
Journal:  Physiol Rev       Date:  2007-01       Impact factor: 37.312

Review 5.  Superoxide dismutase mimics: chemistry, pharmacology, and therapeutic potential.

Authors:  Ines Batinić-Haberle; Júlio S Rebouças; Ivan Spasojević
Journal:  Antioxid Redox Signal       Date:  2010-09-15       Impact factor: 8.401

6.  Elevated synaptic activity preconditions neurons against an in vitro model of ischemia.

Authors:  Joseph S Tauskela; Hung Fang; Melissa Hewitt; Eric Brunette; Tarun Ahuja; Jean-Philippe Thivierge; Tanya Comas; Geoffrey A R Mealing
Journal:  J Biol Chem       Date:  2008-10-09       Impact factor: 5.157

7.  Orally available Mn porphyrins with superoxide dismutase and catalase activities.

Authors:  Rosalind A Rosenthal; Karl D Huffman; Leslie W Fisette; Christy A Damphousse; Wyeth B Callaway; Bernard Malfroy; Susan R Doctrow
Journal:  J Biol Inorg Chem       Date:  2009-06-06       Impact factor: 3.358

8.  SOD activity of carboxyfullerenes predicts their neuroprotective efficacy: a structure-activity study.

Authors:  Sameh Saad Ali; Joshua I Hardt; Laura L Dugan
Journal:  Nanomedicine       Date:  2008-07-24       Impact factor: 5.307

9.  Pure manganese(III) 5,10,15,20-tetrakis(4-benzoic acid)porphyrin (MnTBAP) is not a superoxide dismutase mimic in aqueous systems: a case of structure-activity relationship as a watchdog mechanism in experimental therapeutics and biology.

Authors:  Júlio S Rebouças; Ivan Spasojević; Ines Batinić-Haberle
Journal:  J Biol Inorg Chem       Date:  2007-11-29       Impact factor: 3.358

10.  Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle.

Authors:  Kristen A Malkus; Elpida Tsika; Harry Ischiropoulos
Journal:  Mol Neurodegener       Date:  2009-06-05       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.